恆大地產集團擬召開「15恆大03」第二次持有人會議 審議本息展期至明年7月等議案
恆大地產集團公布,將於下周二至周三(27及28日)就2015年公司債券「15恆大03」召開第二次債券持有人會議,擬審議將原定於明年1月8日完成支付「15恆大03」本金及2021年7月8日至2022年7月7日期間的利息,改為將「15恆大03」本金及於2021年7月8日至2023年7月7日期間的利息支付時間,至明年7月8日完成支付。
「15恆大03」於2015年7月8日完成發行,發行規模82億元人民幣,票面利率6.98厘,債券期限為七年期,附第五年底發行人上調票面利率選擇權及投資者回售選擇權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.